Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
about
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry.Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation.Factors driving anticoagulant selection in patients with atrial fibrillation in the United States.Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation.Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic AttackEvaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.Utilization of Dabigatran for Atrial Fibrillation at 3 Tertiary Care CentresNational Trends in Ambulatory Oral Anticoagulant Use.The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial FibrillationThe changing characteristics of atrial fibrillation patients treated with warfarin.Engaging with quality improvement in anticoagulation management.Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory ModelsEffectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011.Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation.Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant.Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.The Utilization of Antithrombotic Therapy in Older Australians With Atrial Fibrillation.Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs.Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.Genes affecting warfarin response-interactive or additive?Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.Use Patterns and Unlabeled Uses of Target-Specific Oral Anticoagulants: A Single-Center Experience.
P2860
Q30853679-389A5276-09E7-42A2-99EA-1B41298B70C9Q30994474-60D09852-4059-4791-9ED1-62CDF977BA5EQ34091490-EE001555-05CA-4292-8B98-B2F88B04DF1FQ34672800-505ADA94-450E-4F1D-8C1A-ADBCFD8352D9Q35235448-16A82C4D-7666-4335-A05D-5ACCA42A0C71Q35836747-AB80DD1A-288C-4A61-9BF8-74659BDACB01Q35883245-FAB991B5-1FA3-42E2-9BDA-94810264FF85Q35966238-90250862-609D-4D06-BBA8-26E74C7CD7C0Q35991733-76F673DE-689C-4CE4-B26F-9B45A97EEE8EQ36161194-0F637DDE-C4B5-433E-BE85-D67D4BC92D11Q36315659-1005EE44-91F8-4EA5-AFB2-0ED5CAA01CE2Q36620779-DE6B04FD-6761-40A2-893A-C7E5774564DEQ36635772-F1C5A57A-3581-4B24-AE8E-9B5921BFA1D4Q36771378-30995165-286F-416B-A074-C93E83E5FB10Q37004184-05B2883A-EECF-43AC-8FF0-F03D3984BBBBQ37076243-20481A3B-2052-49A1-A1A3-70748F08E3D5Q37376804-E1BD7E69-BF6A-4FB7-A6C4-41ABFC4FFE70Q38200587-9991A8DE-DBA0-43EA-899F-31EFC7B6C93AQ38496232-E710F1D1-8957-45EA-AC75-9616C803CF7BQ38551723-71829E78-A51C-4D04-8FD0-B50B52434E1BQ38662571-53D33B2B-40A0-464C-9E97-69B901813E63Q38728028-F292D109-A9BD-4467-9414-BFC3B24E31A0Q38799019-961EA633-0F4F-4F01-BF7F-13D687C749BFQ38972503-A1FB3611-8AF1-4D68-8B8B-1BC3CC450940Q39053849-00041812-E8D2-4312-9784-96AA1097FF73Q39193511-C58CF130-D544-412C-B059-0CBFAD8D2B5FQ39739154-61F170BC-7C6C-4E1B-90F7-8B03D56C973DQ39905570-58C4E1C3-BFF0-45F7-A6B9-F29D971EA48DQ40140300-2C6B21F8-704B-4520-8691-ADB634E0F135Q40242892-33CCD588-4276-4E1A-80CD-9603A708DC5CQ42255919-8D51B191-8E04-4724-AC32-AB6308E59891Q47136340-C87515CE-4631-49AB-84FC-67BF6C8B0D2EQ47571622-58CA9FF8-5751-44F7-B3B8-19B323C956FDQ47581328-1A04AAE6-93A8-4D62-8F36-827398EF677BQ47713452-BB27E5B8-F63C-4552-BE26-1EC2D7F8A000Q48298756-899A7124-25E6-4F0F-84E8-3A53953E3643Q52618065-238895DD-409F-4F17-833F-72C69739F421Q53085520-00D3B14C-50EC-4293-A011-477FBDCC83B3Q55220400-20704F43-B747-401F-B378-1C71AE3191C9
P2860
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@en
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@nl
type
label
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@en
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@nl
prefLabel
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@en
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@nl
P2093
P2860
P50
P356
P1476
Early adoption of dabigatran a ...... atment of atrial fibrillation.
@en
P2093
Benjamin A Steinberg
Bernard Gersh
Dajuanicia N Holmes
Daniel E Singer
Elaine M Hylek
Jack Ansell
Michael D Ezekowitz
Outcomes Registry for Better I ...... AF) Investigators and Patients
Paul Chang
Peter R Kowey
P2860
P304
P356
10.1161/JAHA.113.000535
P577
2013-11-25T00:00:00Z